Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site

about

Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site

Item

http://www.wikidata.org/entity/Q57818339

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Genetically coating oncolytic ...... irus persistence at tumor site

@en

Genetically coating oncolytic ...... irus persistence at tumor site

@nl

type

Item

label

Genetically coating oncolytic ...... irus persistence at tumor site

@en

Genetically coating oncolytic ...... irus persistence at tumor site

@nl

prefLabel

Genetically coating oncolytic ...... irus persistence at tumor site

@en

Genetically coating oncolytic ...... irus persistence at tumor site

@nl

P1476

Genetically coating oncolytic ...... irus persistence at tumor site

@en

P2093

Lihua Tao

http://www.w3.org/2001/XMLSchema#string

Xiaoliu Zhang

http://www.w3.org/2001/XMLSchema#string

Xinping Fu

http://www.w3.org/2001/XMLSchema#string

P2860

A family of proteins that inhibit signalling through tyrosine kinase receptors

Macrophages and cytokines in the early defence against herpes simplex virus

Phagocytic signaling: you can touch, but you can't eat.

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

4T1 Murine Mammary Carcinoma Cells Enhance Macrophage-Mediated Innate Inflammatory Responses.

The mononuclear phagocyte system.

First oncolytic virus approved for melanoma immunotherapy.

P304

34543-34553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.26167

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30349648

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

6195384

http://www.w3.org/2001/XMLSchema#string